Gilead Sciences Inc. (GILD)
-NasdaqGS 55.93 
0.54(0.96%) 4:00PM EDT|After Hours
:
56.45 0.52 (0.93%) 6:44PM EDT - Nasdaq Real Time Price
| Prev Close: | 56.47 |
|---|
| Open: | 57.00 |
|---|
| Bid: | 56.26 x 200 |
|---|
| Ask: | 56.46 x 200 |
|---|
| 1y Target Est: | 63.88 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 55.62 - 58.06 |
|---|
| 52wk Range: | 24.12 - 58.06 |
|---|
| Volume: | 12,766,148 |
|---|
| Avg Vol (3m): | 11,794,900 |
|---|
| Market Cap: | 85.31B |
|---|
| P/E (ttm): | 31.32 |
|---|
| EPS (ttm): | 1.79 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Wed 6:08PM EDT)
- Gilead's Sofosbuvir under European ReviewZacks(Wed 3:55PM EDT)
- Watch This HCV Playerat Motley Fool(Wed 2:49PM EDT)
- Buy Bristol-Myers, Says Citi; Stock Jumps 7%at Barrons.com(Wed 1:18PM EDT)
- Midday Glance: Biotechnology companiesAP(Wed 1:17PM EDT)
- [video] Best Buy: Buy, Sell or Hold?at CNBC(Wed 12:51PM EDT)
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Saysat Bloomberg(Wed 11:45AM EDT)
- Tiger Cub John Griffin's Top Stock Picks For Q2at Seeking Alpha(Wed 11:03AM EDT)
- Early Glance: Biotechnology companiesAP(Wed 10:51AM EDT)
- Gilead Stock Hits New 52-Week High (GILD)at TheStreet(Wed 10:33AM EDT)
- [$$] A Sampling of "High-Conviction" Stocks and Other Namesat Barrons.com(Tue, May 21)
- Gilead's sofosbuvir gets EMA validation, now under assessmentat theflyonthewall.com(Tue, May 21)
- InPlay: Gilead Sciences: European Medicines Agency validates Gilead's Marketing Application for sofosbuvir for the treatment of Hepatitis CBriefing.com(Tue, May 21)
- European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis CBusiness Wire(Tue, May 21)
- Roche, Reloadedat Investopedia(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | 19.29 |
|---|
| P/S (ttm): | 8.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.49 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.13 |
|---|
Business Summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
View More